More than a week has passed since the elections and medtech executives have had some time to consider what President-elect Trump and the new Congress will mean for their business.

Full or partial repeal of the Affordable Care Act is on the table, as is permanent elimination of the medical device excise tax and the possibility of a corporate tax repatriation holiday. What does this mean for device sales, investment in research and development, and the shift toward value-based healthcare?

A few leaders have started to make public comments on the topic. Read on for early comments from these five executives at major medtech companies.

Take the Medical Innovation Tours during the BIOMEDevice San Jose Conference and Expo, December 7-8.